89bio ([[ETNB]] +6.9%) has surged today after Cantor Fitzgerald initiated coverage on the stock with an overweight rating and the price target at $58.00 per share implies as much as ~124.7% premium to the previous close.89bio’s lone asset BIO89-100 is set to undergo a Phase 2b tri...
Corcept Therapeutics ([[CORT]] -1.1%) is trading lower after an update on federal register for clinical trials indicates ‘suspended’ as recruitment status for a Phase 2 clinical trial evaluating Miricorilant in patients with Nonalcoholic Steatohepatitis (NASH).With the...
Shares of Altimmune (ALT) are down 8.0% to $18.01 in afternoon trading despite reporting 2020 results that beat analyst expectations on both EPS and revenue.Total net loss more than doubled between 2019 and 2020 from $20.5M to $49M.Revenues increased from $5.8M to 8.2M, a 41% rise.R...
Shares of Intercept Pharmaceuticals (ICPT) are down 6.2% to $26.84 in morning trading following the release of Q4 2020 results that missed on both EPS and revenue.Revenue in Q4 was $83.3M compared to $71.5M in the year-ago period, a 16.5% increase.Year-over-year net loss fell to $52...
Guggenheim Partners analyst Seamus Fernandez is initiating coverage of Altimmune (ALT) with a buy rating and a $36 price target.Fernandez says his rating is based on Altimmune's novel intranasal COVID-19 vaccine candidate and the "underappreciated opportunity" to engage the expanding in...
Esperion Gets FDA Nod for Nexletol Esperion Therapeutics (ESPR) reported that its lead drug candidate Nexletol has been approved by the FDA for lowering LDL-C in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. The treatment has ...